ERK-Derived Peptide Blocks Nuclear Translocation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of the ERK cascade have limited effectiveness across various cancers and often lead to resistance, particularly in melanomas, due to the inhibition of ERK-dependent negative feedback loops, which results in hyperactivation of upstream signaling components.
Innovation Solution
Development of a peptide, no longer than 20 amino acids, comprising a sequence at least 95% homologous to GQLNHILGILGX1PX2QED, that prevents the nuclear translocation of ERK1/2 by inhibiting its interaction with importin7, thereby blocking ERK's nuclear activity without affecting negative feedback loops.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitors of Rafs or MEK1/2 are used to treat cancer, then ERK cascade is inhibited, but negative feedback loops are also inhibited causing hyperactivation of upstream signaling components
Solution Approach 1:
The invention segments the ERK inhibition process by using a peptide that specifically blocks nuclear translocation of ERK1/2 without inhibiting the entire ERK cascade. This selective segmentation allows downstream nuclear functions to be blocked while preserving cytoplasmic functions and negative feedback loops.
Solution Approach 2:
The peptide acts as an intermediary molecule that specifically binds to ERK1/2 to prevent its nuclear translocation. This intermediary approach blocks the harmful nuclear activity while allowing the rest of the signaling cascade to function normally, including negative feedback mechanisms.
2Reliability
If Raf/MEK inhibitors are used to treat melanoma, then initial response is achieved, but resistance develops within several months
Solution Approach 1:
Instead of inhibiting upstream components (Raf/MEK) as conventional approaches do, the invention inverts the approach by directly targeting ERK1/2 nuclear translocation. This inversion bypasses the resistance mechanisms that develop against upstream inhibitors and provides sustained treatment effectiveness.
Solution Approach 2:
The invention extracts the nuclear translocation function from ERK1/2 activity by using a peptide that specifically blocks nuclear entry. This extraction allows the peptide to prevent harmful nuclear functions while preserving other ERK functions, thereby avoiding resistance development.
3Productivity
If ERK cascade is inhibited to achieve anti-cancer effect, then proliferation is reduced, but normal cellular processes are also affected
Solution Approach 1:
The peptide applies local quality control by specifically blocking ERK1/2 nuclear translocation while leaving cytoplasmic ERK functions intact. This localized inhibition affects only nuclear processes involved in proliferation while preserving normal cellular processes that depend on cytoplasmic ERK activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively inhibits ERK1/2 nuclear translocation and proliferation in cancer cells, including resistant melanoma cells, while sparing normal cells, leading to apoptosis in B-Raf mutant cancer cells and inhibiting tumor growth in xenograft models without affecting AKT activity.
Implementation Method 1
the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus
Data Source
AI summary
An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.